Encure 0.5 Mg Tablets

Description

What Is Encure 0.5mg Tablet?

Encure 0.5mg Tablet is an oral prescription antiviral medication manufactured by Emcure Pharmaceuticals Ltd. Each film-coated tablet contains Entecavir 0.5 mg.

Encure belongs to the pharmacological class of nucleoside reverse transcriptase inhibitors (NRTIs) and is classified chemically as a guanosine nucleoside analogue. It is prescribed under specialist medical supervision (such as by a hepatologist, gastroenterologist, or infectious disease specialist) for the management of Chronic Hepatitis B Virus (HBV) infection in adult and pediatric patients with evidence of active viral replication and liver inflammation.

The 0.5mg strength is the standard, globally recognized first-line starting dose for treatment-naive patients who have never previously taken nucleoside analogue antiviral medications (such as lamivudine).

Quick Product Fact Sheet

• Brand Name: Encure 0.5mg Tablet
• Active Ingredient: Entecavir (0.5 mg)
• Manufacturer: Emcure Pharmaceuticals Ltd.
• Therapeutic Class: Antiviral agent
• Pharmacological Class: Guanosine nucleoside analogue / NRTI
• Dosage Form: Film-coated oral tablet
• Packaging: Strip or bottle of 10 or 30 tablets
• Standard Adult Dose: One 0.5mg tablet taken orally once daily on an empty stomach
• Primary Indication: Chronic Hepatitis B (HBV) in treatment-naive adult and pediatric patients

How Encure 0.5mg Works

The Hepatitis B virus replicates inside human liver cells (hepatocytes) using its own specialized viral enzyme, HBV DNA polymerase.

Entecavir acts as a false building block designed to inhibit this enzyme. Once absorbed, it is converted inside host cells by cellular kinases into its biologically active form: entecavir triphosphate.

Active entecavir triphosphate competes with the natural substrate (deoxyguanosine triphosphate) and directly blocks all three primary enzymatic functions of the HBV DNA polymerase:

• Base Priming: Blocks the pre-genomic initiation step required to start building new viral DNA strands.
• Reverse Transcription: Inhibits the transcription of negative-strand DNA from viral pregenomic RNA.
• Positive-Strand DNA Synthesis: Stops the formation and elongation of the complementary positive-strand viral DNA.

By blocking these three distinct stages of viral replication, Encure effectively reduces the amount of Hepatitis B virus in the body to undetectable levels. This halts active liver cell injury, reduces elevated liver enzymes, and significantly lowers the long-term risk of developing liver cirrhosis and hepatocellular carcinoma (liver cancer).

Approved Clinical Indications

Encure 0.5mg Tablet is indicated for adult and pediatric patients (2 years of age and older, weighing at least 10 kg with appropriate dosing formulations) in the following settings:

• Compensated Liver Disease in Treatment-Naive Adults: Indicated for adults with chronic hepatitis B infection who have evidence of active viral replication, persistently elevated liver enzymes (ALT or AST), or histologically active liver inflammation who have not received prior nucleoside analogue therapy.
• Compensated Liver Disease in Pediatric Patients: Indicated for treatment-naive pediatric patients aged 2 years and older with active viral replication and abnormal liver enzymes or active histological liver injury.
• HIV/HBV Co-Infection (Only with Complete cART): Can be used to manage Hepatitis B in patients co-infected with HIV, provided they are simultaneously receiving an effective, complete combination antiretroviral therapy (cART) regimen for their HIV infection.

Important Note: Encure does not cure Hepatitis B permanently and does not prevent the transmission of HBV to others through sexual intercourse, sharing needles, or contact with infected blood.

Standard Dosage and Administration Guidelines

Encure 0.5mg must be taken strictly as prescribed by your treating doctor.

Standard Adult Dosage

• Standard Adult Dose (Treatment-Naive): One 0.5mg tablet taken orally once daily.

The Strict Empty-Stomach Requirement

Food significantly delays and reduces entecavir absorption into the bloodstream. You must take Encure on an empty stomach:

• Take the tablet at least 2 hours before a meal, OR
• Wait at least 2 hours after your last meal or snack before taking your dose.

How to Take: Swallow the tablet whole with a full glass of plain water. Do not chew, crush, break, or dissolve the tablet.

Daily Consistency: Take your tablet at the exact same time every day to maintain steady medicine concentrations in the bloodstream.

Dose Adjustments for Reduced Kidney Function

Entecavir is eliminated primarily through the kidneys via glomerular filtration and active tubular secretion. Patients with impaired renal filtration require adjusted dosing intervals:

• 50 mL/min or higher: One 0.5mg tablet every 24 hours (standard daily dose)
• 30 to 49 mL/min: One 0.5mg tablet every 48 hours
• 10 to 29 mL/min: One 0.5mg tablet every 72 hours
• Hemodialysis Patients: One 0.5mg tablet every 7 days (administered immediately after dialysis)

Missed Dose Instructions

• If you miss a dose by less than 12 hours, take it on an empty stomach as soon as you remember.
• If you are within 12 hours of your next scheduled dose, skip the missed dose and resume your regular schedule the following day.
• Never take two tablets at once to make up for a missed dose.

Potential Side Effects & Clinical Management

Encure 0.5mg is generally well tolerated, with most adverse effects being mild and self-limiting.

Common Side Effects

• Nervous System: Headache, fatigue, dizziness, or insomnia (trouble sleeping).
• Digestive: Mild nausea, diarrhea, indigestion, or upper abdominal discomfort.
• Liver Enzymes: Temporary, mild elevations in alanine aminotransferase (ALT) levels as the immune system clears infected liver cells.

Serious Warnings (Seek Immediate Medical Attention)

• Severe Hepatitis B Exacerbations (Black Box Warning): Discontinuing Encure abruptly can trigger sudden, severe, and potentially fatal reactivation of the Hepatitis B virus. Never stop taking this medicine without your doctor’s supervision.
• Lactic Acidosis and Severe Fatty Liver (Hepatomegaly with Steatosis): A rare but serious metabolic complication associated with nucleoside analogues. Seek urgent medical care for deep muscle aches, rapid or difficult breathing, severe stomach pain, cold hands and feet, or sudden extreme fatigue.
• Undiagnosed HIV Resistance Risk: If an individual has an untreated or undiagnosed HIV infection, taking entecavir alone can cause the HIV virus to mutate and develop resistance to other essential HIV medicines. HIV testing is mandatory before initiating Encure.

Precautions & Routine Safety Monitoring

• HBV DNA Viral Load: Baseline, then every 3 to 6 months to track viral suppression and confirm treatment response.
• Liver Function Tests (ALT, AST, Bilirubin): Baseline, then every 1 to 3 months to monitor liver enzyme normalization or sudden inflammatory spikes.
• Kidney Function (eGFR / Serum Creatinine): Baseline and periodic to determine whether dosing intervals need adjustment.
• HIV-1 Antibody Screening: Mandatory prior to starting therapy to confirm absence of HIV to prevent creating drug-resistant HIV strains.
• Liver Ultrasound / AFP (Alpha-Fetoprotein): Every 6 months to screen for early signs of cirrhosis progression or liver tumors.

Drug Interactions & Substance Warnings

• Kidney-Clearing Medicines: Because entecavir is eliminated through kidney tubules, co-administering it with drugs that reduce kidney function or compete for renal tubular secretion (such as aminoglycosides, cyclosporine, or tacrolimus) can raise entecavir blood levels.
• Alcohol: Strictly avoid or minimize alcohol consumption. Alcohol increases liver inflammation and accelerates liver scarring, working directly against your hepatitis treatment.
• Other Hepatitis B Medicines: Do not combine Encure with other entecavir brands. Inform your doctor if you have previously taken lamivudine, adefovir, or tenofovir.

Special Population Guidance

• Pregnancy: Use only if the potential benefit clearly outweighs the potential risk to the fetus. Consult your doctor if planning pregnancy.
• Breastfeeding: It is unknown if entecavir passes into human breast milk. Breastfeeding is generally not recommended while on treatment unless approved by a physician.
• Kidney Impairment: Dosing intervals must be adjusted if creatinine clearance is below 50 mL/min.
• Pediatric Use: Approved for pediatric patients 2 years of age and older weighing at least 10 kg. Children must be able to swallow tablets or use oral solutions.

Storage and Handling Protocols

• Store tablets at room temperature between 20°C and 25°C (68°F to 77°F).
• Keep tablets in their original packaging, tightly closed, in a dry place protected from direct heat, moisture, and light.
• Keep strictly out of reach of children and pets.

Frequently Asked Questions (FAQs)

Q1: What is the difference between Encure 0.5mg and Encure 1mg?
The 0.5mg strength is standard for patients who have never taken antiviral medications before (treatment-naive). The 1mg strength is reserved for patients whose virus has developed resistance to older medications like lamivudine, or for patients with advanced decompensated liver disease.

Q2: Why must I take Encure 0.5mg on an empty stomach?
Food significantly reduces the amount of entecavir your body absorbs. To ensure that the full dose enters your bloodstream to suppress the virus, you must take it at least 2 hours before or 2 hours after eating.

Q3: Can I stop taking Encure once my viral load becomes undetectable?
No. An undetectable viral load means the medication is working successfully to keep the virus suppressed. Stopping treatment can cause the virus to rebound rapidly, leading to severe liver flares and potentially life-threatening liver failure.

Q4: Does Encure cure Hepatitis B permanently?
Encure does not remove dormant viral genetic material (cccDNA) from the liver, so it is not a permanent cure. However, long-term daily use suppresses the virus, allows the liver to heal, and significantly lowers the lifetime risk of cirrhosis and liver cancer.

Medical Disclaimer: This clinical guide is strictly for educational and informational purposes and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified hepatologist, gastroenterologist, or healthcare provider before starting, stopping, or modifying any antiviral therapy.

References

• U.S. Food and Drug Administration (FDA): Baraclude (entecavir) Full Prescribing Information. View Source
• National Center for Biotechnology Information (NCBI): StatPearls Review: Entecavir Pharmacology, Indications, and Clinical Use. View Source
• European Association for the Study of the Liver (EASL): Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. View Source
• MedlinePlus (U.S. National Library of Medicine): Entecavir Monograph & Patient Instructions. View Source